North America Multiplex Assays Market– Industry Trends and Forecast to 2026

  • In Vitro Diagnostics
  • Published Report
  • Nov 2018
  • North America
  • 350 Pages
  • No of Tables: 25
  • No of Figures: 67

North America Multiplex Assays Market, By Products & Services (Reagents & Consumables, Instruments & Accessories, Software & Services), Type (Nucleic Acid Multiplex Assays, Protein Multiplex Assays, Cell-Based Multiplex Assays), Technology (Protein Microarray, Polymerase Chain Reaction, Multiplex Real-Time PCR, Flow Cytometry, Fluorescence Detection, Luminescence, Others), Application (Clinical Diagnostics, Research & Development), End User (Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Research Institutes, Others), Geography (North America)- Industry Trends and Forecast to 2026

A Multiplex Assay is a type of immunoassay that uses magnetic beads or non-magnetic beads to determine multiple analyte in a single sample. A multiplex assay is as similar as that of an ELISA but here in multiplex assays, beads are present that are useful in binding the capture antibody. Multiplex assays are common because of their benefits nowadays in research than in clinical settings.

Protein immunoassays give data regarding quantities and forms of endogenous proteins in a given sample. Uniplex enzyme immunoassays such as enzyme-linked immunosorbent assay (ELISA) used for protein measurement from past years but they are time consuming and found to be more costly. When comparing ELISA with multiplex assays, multiplex assays offer more accurate quantitative information in a single analysis for number of analysis.

North America multiplex assays market is expected to reach a healthy CAGR of 7.4% in the forecast period of 2019 to 2026. The new market report contains data for historic years 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation: North America Multiplex Assays Market 

A North America multiplex assay market is categorized into five notable segments which are products & services, type, technology, application and end user.

  • On the basis of product & services, the market is segmented into reagents & consumables, instruments & accessories and software and services. In 2019, reagents & consumables segment is expected to dominate the North America multiplex assays market with 63.2% market share and is expected to grow at the highest CAGR of 7.7% in the forecast period of 2019 to 2026.

    • In September 2014, F. Hoffmann-La Roche Ltd launched new fully automated molecular diagnostic systems named as cobas 6800/8800 Systems. These systems offer results in a very short time along with highest testing capacity. With this launch the company has increased their product portfolio in market in diagnostics field.

  • On the basis of type, the market is segmented into protein multiplex assays, nucleic acid multiplex assays and cell-based multiplex assays. Protein multiplex assays are sub-segmented into planar protein assays and bead-based protein assays. Nucleic acid multiplex assays are sub-segmented into planar nucleic acid assays and bead-based nucleic acid assays.

    • In 2019, a nucleic acid multiplex assay segment is expected to dominate the North America multiplex assays market with 63.2% market share and is expected to grow at the highest CAGR of 7.7% in the forecast period of 2019 to 2026.
    • In June 2015, Abcam plc, launched a range of multiplex miRNA profiling assays. The launched assay has the ability to give high-throughput validation of miRNA biomarkers on the basis of Abcam’s new Firefly particle technology. Launching this product was the opportunities to Abcam for its Firefly particle technology that bring the North America researchers for miRNA research.

  • On the basis of technology, the market is segmented into flow cytometry, fluorescence detection, luminescence, multiplex real-time PCR, polymerase chain reaction (PCR), protein microarray and others. In 2019, protein microarray segment is expected to dominate the North America multiplex assays market with 31.7% market share and is expected to grow at the CAGR of 7.5% in the forecast period of 2019 to 2026. However, polymerase chain reaction (PCR) segment is expected to grow at the highest CAGR of 8.3% in the forecast period of 2019 to 2026.

    • In July 2018, BD (Becton, Dickinson and Company) launched BD AbSeq assay for simultaneous RNA and protein expression analysis assay. The systems include the BD Rhapsody Express system and the BD single-cell multiplexing kit. Launch of this product helped in increasing one more product in company’s product portfolio.

  • On the basis of application, the market is segmented into research & development and clinical diagnostics. Research & development is sub-segmented into drug discovery & development and biomarker discovery & validation. Clinical diagnostics is sub-segmented into infectious diseases, cancer, cardiovascular diseases, infectious diseases, autoimmune diseases, allergies, nervous system disorders, metabolism & endocrinology disorders and others.

    • In 2019, clinical diagnostics segment is expected to dominate the North America multiplex assays market with 54.9% market share and is expected to grow at the highest CAGR of 7.6% in the forecast period of 2019 to 2026.
    • In June 2015, MESO SCALE DIAGNOSTICS, LLC. at the 2015 AAPS National Biotechnology Conference, launched its new Biomarker Services. This service offered biomarker screening and assay development services to their customer for discovery and exploratory studies to validated products.

  • On the basis of end user the market is segmented into pharmaceutical & biotechnology companies, research institutes, hospitals, clinical laboratories and others. In 2019, hospitals segment is expected to dominate the North America multiplex assays market with 33.7% market share and is expected to grow at the highest CAGR of 8.5% in the forecast period of 2019 to 2026.

    • In January 2016, Thermo Fisher Scientific acquired Affymetrix (U.S.). The acquisition of Affymetrix with Thermo Fisher Scientific helped Thermo Fisher Scientific Company in strengthening the biosciences field and creating new market opportunities for in genetic analysis.

Competitive Analysis: North America Multiplex Assays Market 

Some of the prominent participants operating in this market are BD, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Cepheid, Siemens AG, Hologic Inc., Luminex Corporation. , MESO SCALE DIAGNOSTICS, LLC., QIAGEN, PerkinElmer Inc. , Illumina, Inc. , AGENA BIOSCIENCE, INC. , Olink , Randox Laboratories Ltd., Bio-Techne. , Agilent Technologies, Agilent Technologies, Sysmex Corporation and among others..

Product launch:

  • In August 2017, Quanterix Corporation announced expansion for its single molecule array, or In June 2018, QIAGEN (Germany) launched the QIAseq 16S/ITS Panels and UCP Multiplex PCR Kit. This kit was launched along with a new generation of reagents that allows the most accurate quantification and qualitative analysis from complex microbiome samples. This product provides a comprehensive and robust profiling of bacterial and fungal communities. With this launch, one more product got added to the company’s product portfolio.
  • In May 2018, Bio-Rad Laboratories, Inc. launched the Bio-Plex Pro Human Cytokine Screening Panel. This product is the first validated high-performance multiplex assay on the market. The panel has the ability to identify and quantify 48 different analytes. This is applicable for identification and estimation of analytes for heart disease, autoimmunity and allergy, cancer, and many other conditions. Launching this product helped the company in increasing their product portfolio.
  • In June 2018, QIAGEN launched the QIAseq 16S/ITS Panels and UCP Multiplex PCR Kit. This kit was launched with a new generation of reagents to allow the most accurate microbial community profiling from complex microbiome samples. This product provides comprehensive and robust profiling of bacterial and fungal communities. With this launch one more product got added to company’s product portfolio.

Research Methodology: North America Multiplex Assays Market 

Primary Respondents: Key Opinion Leaders (KOL’s): Manufacturer, Healthcare Professionals, Doctors, Nurses, Medical practitioners. Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and, National Sales Managers


SKU-
CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
BUY NOW ADD TO CART
Why Choose Us
REQUEST FOR SAMPLE